KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Finished Goods (2017 - 2020)

Amneal Pharmaceuticals has reported Finished Goods over the past 4 years, most recently at $222.2 million for Q1 2020.

  • Quarterly results put Finished Goods at $222.2 million for Q1 2020, changed N/A from a year ago — trailing twelve months through Mar 2020 was $222.2 million (changed N/A YoY), and the annual figure for FY2019 was $150.7 million, down 31.93%.
  • Finished Goods for Q1 2020 was $222.2 million at Amneal Pharmaceuticals, up from $150.7 million in the prior quarter.
  • Over the last five years, Finished Goods for AMRX hit a ceiling of $250.6 million in Q2 2018 and a floor of $105.8 million in Q4 2017.
  • Median Finished Goods over the past 4 years was $208.7 million (2018), compared with a mean of $193.7 million.
  • Biggest five-year swings in Finished Goods: surged 109.19% in 2018 and later plummeted 31.93% in 2019.
  • Amneal Pharmaceuticals' Finished Goods stood at $105.8 million in 2017, then soared by 109.19% to $221.4 million in 2018, then plummeted by 31.93% to $150.7 million in 2019, then surged by 47.4% to $222.2 million in 2020.
  • The last three reported values for Finished Goods were $222.2 million (Q1 2020), $150.7 million (Q4 2019), and $168.2 million (Q3 2019) per Business Quant data.